COMP <GO>
KYMR vs JNJ // REVENUE GROWTH (YOY)
Kymera Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: KYMR 4
— JNJ 9
▲ REVENUE GROWTH (YOY) LEADER: JNJ
LAST: $126.63 (+3.29%) • MKT CAP: $10.19B
revenue-growth
-16.70%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYMR VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KYMR | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 0.00% | 67.90% | -67.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.40% | 25.50% | -46.90 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.30% | 2.97% | -5.27 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.50% | +39.50 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -16.70% | 6.00% | -22.70 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | KYMR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.20% | -0.50 | KYMR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.3 | 60.4 | +8.98 | KYMR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.08 | -0.13 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.4x | 23.0x | +7.40 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.19B | $662.49B | -$652.30B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KYMR REV | JNJ REV | KYMR GROSS % | JNJ GROSS % | KYMR FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $39.2M | $94.19B | 0.0% | 67.9% | -$234.3M | $19.70B |
| FY 2024 | $47.1M | $88.82B | 0.0% | 69.1% | -$207.3M | $19.84B |
| FY 2023 | $78.6M | $85.16B | 44.0% | 44.0% | -$106.4M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYMR // BETA 0.95
JNJ // BETA 1.08